The biology of VEGF and its receptors, Nat Med, vol.9, issue.6, p.12778165, 2003. ,
The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, Curr Drug Targets, vol.18, issue.10, p.27138763, 2017. ,
Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer, Cardiovasc Hematol Agents Med Chem, 2017. ,
Visvikis-Siest S. Heritability for plasma VEGF concentration in the Stanislas family study, Ann Hum Genet, vol.71, p.17227476, 2007. ,
Identification of cis-and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels, Circ Res, vol.109, issue.5, p.21757650, 2011. ,
Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies, PLoS Genet, vol.12, issue.2, p.26910538, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01708531
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning, Cytokine Growth Factor Rev, vol.25, issue.1, p.24332926, 2014. ,
VEGF-A splicing: the key to anti-angiogenic therapeutics?, Nature reviews Cancer, vol.8, issue.11, p.18923433, 2008. ,
Molecular diversity of VEGF-A as a regulator of its biological activity, Microcirculation, vol.16, issue.7, p.19521900, 2009. ,
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis, J Biol Chem, vol.285, issue.8, pp.5532-5572, 2010. ,
VEGF-A splicing: the key to anti-angiogenic therapeutics?, Nat Rev Cancer, vol.8, issue.11, p.18923433, 2008. ,
Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization, J Immunol, vol.172, issue.7, p.15034080, 2004. ,
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward. Cold Spring Harb Perspect Med, vol.2, 2012. ,
Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT()) and standard density gradient, BMC Immunol, vol.16, 2015. ,
The Dictionary of Cell and Molecular Biology, 2012. ,
PBMC Basic: Sanguine Biosciences, 2012. ,
Vascular endothelial growth factor and its relationship to inflammatory mediators, Clin Cancer Res, vol.13, issue.10, p.17504979, 2007. ,
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease, Biochim Biophys Acta, vol.1843, issue.11, p.24892271, 2014. ,
Lymphocyte responses and cytokines, Cell, vol.76, issue.2, pp.241-51, 1994. ,
Adhesion molecules and their role in vascular disease, Am J Hypertens, vol.14, issue.6, p.11411765, 2001. ,
Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion, FASEB J, vol.16, issue.11, p.12205052, 2002. ,
Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells, Oncogene, vol.22, issue.50, p.14603252, 2003. ,
Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages, J Pathol, vol.227, issue.1, p.22367978, 2012. ,
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts, Clin Exp Immunol, vol.147, issue.3, p.17302909, 2007. ,
Interleukin-13 and Interleukin-4 Induce Vascular Endothelial Growth Factor Release from Airway Smooth Muscle Cells: Role of Vascular Endothelial Growth Factor Genotype, Am J Respir Cell Mol Biol, vol.34, issue.2, p.16210693, 2006. ,
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma, J Biomed Sci, vol.11, issue.4, p.15153787, 2004. ,
MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease, Pediatr Res, vol.80, issue.3, p.27089500, 2016. ,
The peripheral blood mononuclear cell microRNA signature of coronary artery disease, Biochem Biophys Res Commun, vol.394, issue.3, p.20230787, 2010. ,
Peripheral blood gene expression profiling for cardiovascular disease assessment, Genomic Med, vol.1, issue.3, pp.105-117, 2007. ,
Aldose Reductase Gene Expression Is Increased in Diabetic Nephropathy1, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.7, pp.2294-2302, 1997. ,
Use of RNA sequencing to evaluate rheumatic disease patients, Arthritis Res Ther, vol.17, issue.1, p.167, 2015. ,
A Blood RNA Signature Detecting Severe Disease in Young Dengue Patients at Hospital Arrival, J Infect Dis, 2018. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02088893
Correlation between obesity and inflammation in cardiovascular diseases-evaluation of leptin and inflammatory cytokines, Open Journal of Endocrine and Metabolic Diseases, vol.2, issue.02, p.7, 2012. ,
Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma, Int J Cancer, vol.63, issue.3, p.7591233, 1995. ,
Inflammation and metabolic disorders, Nature, vol.444, issue.7121, p.17167474, 2006. ,
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts, Clin Exp Immunol, vol.147, issue.3, p.17302909, 2007. ,
Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2, Proc Natl Acad Sci U S A, vol.86, issue.10, p.2786204, 1989. ,
Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages, J Pathol, vol.227, issue.1, p.22262122, 2012. ,
IL-4 Causes Hyperpermeability of Vascular Endothelial Cells through Wnt5A Signaling, PLoS One, vol.11, issue.5, 2016. ,
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview, J Interferon Cytokine Res, vol.29, issue.6, p.19441883, 2009. ,
Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A, Blood, vol.105, issue.4, p.15498848, 2005. ,
Significance of Macrophage Chemoattractant Protein-1 in Macrophage Recruitment, Angiogenesis, and Survival in Human Breast Cancer. Clin Cancer Res, vol.6, issue.8, p.10955814, 2000. ,
Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells, American Journal of Physiology-Heart and Circulatory Physiology, vol.286, issue.5, p.14693680, 2004. ,
Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization, Biomaterials, vol.31, issue.11, p.20110124, 2010. ,
Interleukin 6 induces the expression of vascular endothelial growth factor, J Biol Chem, vol.271, issue.2, p.8557680, 1996. ,
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway, Oncogene, vol.22, issue.10, p.12629515, 2003. ,
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas, Int J Cancer, vol.119, issue.6, p.16642474, 2006. ,
The Cytokines of the Immune System: The Role of Cytokines in Disease Related to Immune Response, 2015. ,
Biologic basis for interleukin-1 in disease, Blood, vol.87, issue.6, p.8630372, 1996. ,
Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer, Hepatobiliary Pancreat Dis Int, vol.4, issue.3, p.16109537, 2005. ,
Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells, Eur J Endocrinol, vol.152, issue.2, p.15745939, 2005. ,
Epidermal growth factor, J Biol Chem, vol.265, issue.14, p.2186024, 1990. ,
EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models, PLoS One, vol.11, issue.11, p.27806094, 2016. ,
Roles for growth factors in cancer progression, Physiology (Bethesda), vol.25, issue.2, pp.85-101, 2010. ,
EGF-ERBB signalling: towards the systems level, Nature Reviews Molecular Cell Biology, vol.7, p.16829981, 2006. ,
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy, Ann Oncol, vol.17, issue.7, pp.109-123, 2006. ,
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications, Nat Clin Pract Oncol, vol.5, issue.9, p.18594498, 2008. ,
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents, Mol Cancer Res, vol.5, issue.3, p.17374728, 2007. ,
Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer, Gastroenterology, vol.138, issue.6, p.20420953, 2010. ,
Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing, Biochem Biophys Res Commun, vol.235, issue.3, p.9207183, 1997. ,
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis, BMC Cancer, vol.5, p.16202150, 2005. ,
Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer, Int J Cancer, vol.140, issue.10, p.27943279, 2017. ,
An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease, vol.20, pp.1464-71, 2014. ,
Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease, Genes (Basel), vol.9, issue.2, 2018. ,
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis, Circ Res, vol.109, issue.3, p.21636803, 2011. ,
Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis, Am J Respir Crit Care Med, vol.196, issue.4, p.28661183, 2017. ,
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma, Cancer Res, vol.62, issue.14, p.12124351, 2002. ,
Circulating levels of antiangiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios, Am J Cancer Res, vol.5, issue.6, p.26269767, 2015. ,
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy, Br J Cancer, vol.98, issue.8, p.18349829, 2008. ,
Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?, World J Gastroenterol, vol.10, issue.5, p.14991937, 2004. ,
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas, PLoS One, vol.5, issue.5, p.20502715, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00490677
A computational analysis of pro-angiogenic therapies for peripheral artery disease, Integr Biol (Camb), vol.10, issue.1, pp.18-33, 2018. ,
Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies, Oncotarget, vol.8, issue.6, p.27999187, 2017. ,